This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Molecular-level biochemicalassays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI).
Both are a focus for exciting new small-molecule drug therapeutics that target cancers and autoimmune disorders. The Transcreener HTS Assay platform accelerates these efforts by providing robust and easy-to-use biochemicalassays for key enzymes in the pathways.
Based on the druggability of DR3penA, we sought to investigate its effects on respirable particulate silicon dioxide (SiO 2 )- and soluble chemical paraquat (PQ)-induced pulmonary fibrosis in this study by using western blot, RT-qPCR, immunofluorescence, H&E and Masson staining, immunohistochemistry and serum biochemicalassays.
We have integrated structural and quantitative proteomics with biochemicalassays to decipher the mode of action of covalent USP30 inhibition by a smallmolecule containing a cyanopyrrolidine reactive group, USP30-I-1. The inhibitor demonstrated high potency and selectivity for endogenous USP30 in neuroblastoma cells.
The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We often screen using a biochemicalassay, but we can conduct cell-based screening as well. We need to build the assays that we need for compound screening.
These dual-covalent smallmolecules reversibly react with a nucleophilic amino acid on each of the partner proteins to dynamically crosslink the protein complex. Based on a focused library of dual-reactive smallmolecules, a molecular glue tool compound was rapidly developed.
Progress from target ID through to IND submission in conventional workflows can take upwards of 6+ years, where success hinges on iterative cycles of DMTA.
Small screens are better than large ones. Biochemicalassays have the highest success rate. Smallmolecules are making a comeback. For the minority of companies working with large molecules and biologics, most said they were in a phase of clinical research. Biologics are booming. Think again.
In any case, it needed to be made clear that the quality criteria proposed by the authors for covalently acting small-molecule probes only apply to probes that act irreversibly. Carefully designed biochemicalassays used in determining IC50 values can be well-suited as surrogates for k.inact/K.i measurements. (
I’ll start with the significance section and my comments are italicized in red: Tricyclic tetrahydroquinolines (THQs) are a family of lesser studied pan-assay interference compounds (PAINS) [The authors need to provide specific examples of tricyclic THQs that have been actually been shown to exhibit pan-assay interference to support this claim.]
Å resolution) 6 is now being targeted for smallmolecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemicalassays.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content